Benefit profile of anticoagulant therapy in sepsis: A nationwide multicentre registry in Japan

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Yamakawa, Kazuma ^a,b   Umemura, Yutaka ^b   Hayakawa, Mineji ^c   Kudo, Daisuke ^d   Sanui, Masamitsu ^e   Takahashi, Hiroki ^b   Yoshikawa, Yoshiaki ^a   Hamasaki, Toshimitsu ^f   Fujimi, Satoshi ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Anticoagulants; DIC; Disseminated intravascular coagulation; Retrospective studies; Sepsis; Subgroup analysis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN; PROTEINASE INHIBITOR; RECOMBINANT THROMBOMODULIN;

ADULT; AGED; ANTICOAGULANT THERAPY; APACHE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE REGISTRY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; VERY ELDERLY; CLINICAL TRIAL; JAPAN; MORTALITY; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORE; ORGANIZATION AND MANAGEMENT; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; JAPAN; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORES; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS;

EID: 84979740931     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-016-1415-1     Document Type: Article

References (32)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840-51.
2. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-30.
3. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559-66.
4. Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, et al. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007;28:411-7.
5. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40:2704-8.
6. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131:383-9.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
8. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64.
9. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.
10. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297.
11. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47.
12. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35:349-54.
13. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069-79.
14. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34:285-92.
15. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7.
16. Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.
17. Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115:1157-66.
18. Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
19. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36:145-50.
20. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-31.
21. D'Agostino Jr RB, D'Agostino Sr RB. Estimating treatment effects using observational data. JAMA. 2007;297:314-6.
22. Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36:1993-2003.
23. Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33.
24. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016. in press.
25. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
26. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112:640-8.
27. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2:67.
28. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003;29:894-903.
29. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508-19.
30. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115(4):712-28.
31. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol. 2013;79:294-8.
32. Ito T, Kakihana Y, Maruyama I. Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases. Expert Opin Ther Targets. 2015;11:1-8.